Company: GIFLF
Filing Date: 2025-02-26
Form Type: 6-K
Source: 0001104659-25-017501
Chunk: 4

Company: Grifols SA
Filing Date: 2025-02-26
Form: 6-K
Chunk 4
---
 the conference call.

INVESTORS:

Investors Relations & Sustainability

inversores@grifols.com

sostenibilidad@grifols.com

Tel. +34 93 571 02 21

MEDIA CONTACTS:

| Grifols                                
 Press Office                           
 media@grifols.com                      
 / Tel. +34 93 571 00 02                |
| Spain                                  
 Duomo Comunicación                     
 Tel.: +34 91 311 92 89 – +34 91 311    
 92 90                                  
 Raquel Lumbreras (M. +34 659 572 185)  
 Raquel_lumbreras@duomocomunicacion.com 
 Borja Gómez (M. +34 650 402 225)       
 Borja_gomez@duomocomunicacion.com      |

About Grifols

Grifols is a global healthcare company founded
in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived
medicines and transfusion medicine, the company develops, produces, and provides innovative healthcare services and solutions in more
than 110 countries.

Patient needs and Grifols’ ever-growing
knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company’s innovation in both plasma
and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas:
immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues
to grow its network of donation centers, the world’s largest with close to 400 across North America, Europe, Africa and the Middle
East, and China.

Page 3 of 4

As a recognized leader in transfusion medicine,
Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical
diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing
pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and
healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more
than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality,
safety, and ethical leadership.

In